ArticleJournal of medical biochemistry2025
The gene panel with methylation-related genes and clinical factors for predicting overall survival of endometrial cancer.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to identify novel methyla-tion-based prognostic biomarkers for endometrial cancer (EC) to facilitate early diagnosis and treatment. To explore methylation-related prognostic markers in endometrial tis-sue by analyzing TCGA data and to establish a methylation-based risk model for EC patients. Methods: We systematically analyzed methylation-related gene expression and prognostic significance in 409 EC patients using TCGA DNA methylation data. DNA methy-lation biomarkers were identified through consensus clus-tering and weighted gene co-expression network analysis (WGCNA). The clusterProfiler algorithm was employed to determine key signaling pathways across different sub-groups. A gene panel targeting critical DNA methylation sites was subsequently constructed. Results: A methylation-related prognostic risk model was developed, incorporating five CpG sites: cg01416891, cg00082235, cg01493517,cg03811891,and cg05317207. The model demonstrated strong predictive performance, with high-risk patients exhibiting significantly poorer prog-noses compared to low-risk patients. A gene panel was also established to predict prognosis across different EC risk groups. Conclusions: The methylation-related gene panel model serves as a reliable prognostic biomarker for EC, offering potential for enhanced early diagnosis and personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.